Masimo delivered Q3 results that mostly aligned with guidance, yet it faces challenges in its non-healthcare segment.

Shares of Masimo Co. (NASDAQ:MASI – Get Free Report) have received an average rating of “Moderate Buy” from the seven ...

Fintel reports that on November 6, 2024, Raymond James upgraded their outlook for Masimo (NasdaqGS:MASI) from Market Perform ...

The dispute dates to 2013 when Apple sought Masimo’s technology to install pulse oximetry on its watch. Email correspondence ...

Masimo sells a range of devices used for patient monitoring that feature a proprietary pulse oximetry technology called Signal Extraction Technology (SET). In the latest update on that patent spat ...

Assess the potential impact of proposed tariffs on Chinese imports on the MedTech industry, based on insights from Wall ...

Masimo Co. (NASDAQ:MASI – Get Free Report) reached a new 52-week high during trading on Wednesday following a better than expected earnings announcement.The stock traded as high as $173.90 and ...

Revenue: US$504.6m (up 5.4% from 3Q 2023). Net income: US$9.80m (down 7.5% from 3Q 2023). Profit margin: 1.9% (down from 2.2% in 3Q 2023). The decrease in margin was driven by higher expenses. EPS ...

In its first earnings report since the departure of longtime CEO Joe Kiani, Masimo said Tuesday it is focused on reducing spending to drive long-term growth. The company continues to evaluate ...

Piper Sandler raised the firm’s price target on Masimo (MASI) to $180 from $165 and keeps an Overweight rating on the shares. The firm notes the company announced Q3 revenue of $505M finished ...

North America continues to dominate the paediatric and neonatal testing kits market, driven by high birth rates, advanced ...

When asked by Pulse PCN what measures would be put in place to help PCNs mitigate the impact of this on their Additional Roles Reimbursement Scheme (ARRS) staff budgets, the Department for Health and ...